A novel approach to directly observed therapy for tuberculosis in an HIV-endemic area.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 11189809.
- Also identified by PMC identifier 1446511.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study evaluated a novel approach to the delivery of directly observed therapy (DOT) for tuberculosis in Haiti. A total of 194 patients (152 HIV seropositive, 42 HIV seronegative) received daily unsupervised triple-drug therapy for 4 to 8 weeks, followed by twice-weekly 2-drug therapy for the remainder of the 6-month period. DOT was deferred until initiation of the twice-weekly phase. A total of 169 of 194 patients (87.1%) completed the 6-month course. The program of deferred DOT had an effectiveness of 85%. Overall cost was reduced by approximately 40%. Flexible approaches to DOT, integrating behavioral knowledge, cost considerations, and practicality may improve completion rates and program effectiveness.
Medical subject headings
- Antitubercular Agents
- HIV Seropositivity
- Patient Compliance
- Tuberculosis, Pulmonary